Advanced · 90D
1
Moved up a stage
Setbacks
1
Misses, holds, CRLs
Discontinued
2
Currently discontinued
Catalysts · 6 MO
8
Through Apr 11, 2027
Movement tracking since Oct 9, 2026. 90-day history covers 3 of 29 tracks shown; the rest are not counted as steady, because their history is not yet recorded.
Desk All Pharma Psychedelics Cannabis Digital
Modality All Drug + Therapy Device
Indication All indications Postpartum depression Major depressive disorder Treatment-resistant depression Major depressive disorder with insomnia symptoms Agitation associated with dementia due to Alzheimer's disease Alzheimer's disease psychosis Schizophrenia Schizophrenia, negative symptoms Attention-deficit/hyperactivity disorder Alcohol use disorder Generalized anxiety disorder Social anxiety disorder Post-traumatic stress disorder Insomnia Fragile X syndrome
Search program, generic name, sponsor or ticker
▲ Advanced in 90 days‖ Setback / holdDiscontinued Device and digital programs use FDA authorization stages: a 510(k) is cleared, not approved, though it sits in the last column.
The mental-health pipeline B Behavioral Wire Programs by mechanism and stage · centre is approved or authorized · ticked lines mark a stage gained in 90 days Serotonergic psychedelic Entactogen NMDA modulator GABA-A modulator κ-opioid antagonist Muscarinic M1/M4 Orexin antagonist Monoamine reuptake inhibitor 5-HT2A antagonist GIP / GLP-1 agonist Cannabinoid Nasal chemosensory Neuromodulation & digital PRECLIN. PHASE 1 PHASE 2 PHASE 3 FILED APPROVED AUTHORIZED GH001, TRD, Phase 2 HLP004, GAD, Phase 2 Luvesilocin, PPD, Phase 2 VLS-01, TRD, Phase 2 BPL-003, TRD, Phase 3 COMP360, TRD, Phase 3 DT120, GAD, Phase 3 DT120, MDD, Phase 3 HLP003, MDD, Phase 3 Usona psilocybin, MDD, Phase 3 MDMA-assisted therapy, PTSD, Phase 3 TSND-201, PTSD, Phase 3 AXS-05, AD agitation, Approved AXS-05, MDD, Approved Esketamine, TRD, Approved Zuranolone, PPD, Approved Navacaprant, MDD, Phase 3, discontinued Emraclidine, Schizophrenia, Phase 2 NBI-1117568, Schizophrenia, Phase 3 Cobenfy, Schizophrenia, Approved Seltorexant, MDD + insomnia, Phase 3 Centanafadine, ADHD, Approved Remlifanserin, AD psychosis, Phase 3, setback or on hold Brenipatide, AUD, Phase 3 Brenipatide, MDD, Phase 3 Zygel, Fragile X, Phase 3, discontinued Fasedienol, SAD, Phase 3 CT-155, Schizophrenia, negative, Authorized (FDA cleared), advanced in the last 90 days Rejoyn, MDD, Authorized (FDA cleared) Sleepio / Daylight, GAD, Authorized (FDA cleared) Sleepio / Daylight, Insomnia, Authorized (FDA cleared) Pharma Psychedelics Cannabis Digital Drug + therapy Device behavioralwire.com/pipeline-map © Behavioral Wire · Data as of Oct 9, 2026 Hover a program to trace it across indications; click for the full record. Movement tracking since Oct 9, 2026; 90-day history covers 3 of 29 tracks.
Last reviewed Oct 9, 2026. Each row carries its own verification date, shown in the program detail.